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curve than did the other guidelines.
Conclusion: The current AUA guidelines for the recommendation of
staging bone scans had better prediction and application rates than other
guidelines in our patient cohort.
PD4-2:
BRACHYTHERAPY USING I-125 IMPLANT IN THE TREATMENT OF
LOCALIZED PROSTATE CANCER: KFSYSCC INITIAL EXPERIENCE
Yu-Hung Lin 1, Kuei-Kang Huang 2, Ho-Da Chuang 3, Hung-Chun Skye
Cheng 2, Shu-Jen Chang 1. 1Department of Urology, Koo-Foundation Sun
Yat-Sen Cancer Center, Taipei, Taiwan; 2Department of Radiation Oncology,
Koo-Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan; 3Department of
Medical Physics, Koo-Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
Purpose: Brachytherapy with permanent implant of radioactive seeds is
one of the ﬁrst-line treatments of localized prostate cancer. In Taiwan, this
treatment hasn't been provided in the past years. We conducted a Phase I
clinical trial to observe if we can preform it in good quality.
Materials and Methods: The clinical trial was conducted in KFSYSCC. In-
clusion criteria were: Patients with histologically conﬁrmed, localized
adenocarcinoma of the prostate, clinical stage T1c-2bN0M0, PSA < 20 ng/
ml, Gleason Score < 7, Karnofsky Performance Status > 70, No signiﬁcant
obstructive symptoms, No hip prosthesis, No prior transurethral prostate
surgery, No prior chemotherapy or radiotherapy or hormonal therapy,
prostate volume by trans-rectal ultrasound < 45 cc. Permanent implant of
I-125 seeds with prescription dose of 145Gy were given under general
anesthesia. PSA, IPSS score and IIEF score were recorded in 1, 3, 6, 9, 12 and
every 6 months after treatment.
Results: From May 2013 to April 2014, a total of 11 patients received I-125
seed implant brachytherapy. Clinical stages were T1c, T2a, T2b in 3, 7 and 1
patients each. Gleason Scores were 3+3 in 9 patients and 3+4 in 2 patients.
Pre-treatment PSA was less than 10ng/ml in 7 patients, and between 10-
20ng/ml in 4 patients. Clinical risk groups were low-risk in 7 patients and
intermediate-risk in 5 patients. Complications included 3 patients with
transient urine retention. At 1 year after seed implant, PSAdeclined to<1,1-
2, >2 in 6, 2, 3 patients each. IPSS returned to baseline level in 6-9 months.
IIEF returned to baseline level in 6 of 9 sexually active patients in 1 year.
Conclusion: Seed implant brachytherapy can be done in good quality for
the treatment of prostate cancer in Taiwan.
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Purpose: To report short-term efﬁcacy and safety of abiraterone acetate
and prednisone in metastatic castration-resistant prostate cancer patients
in VGHTC.
Materials and Methods: A total of 25 patients with metastatic castration-
resistant prostate cancer who have progressive disease or have become
intolerance while receiving docetaxel were treated with abiraterone
(1000 mg, once daily) and prednisolone (5 mg, twice daily). Patients
achieving a prostate-speciﬁc antigen (PSA) reduction  50% were
considered as PSA response, as COU-AA301 deﬁnition.
Results: There were 14 patients (56%) achieving PSA response, 6 (24 %)
having stable disease, and ﬁve (20 %) PSA progression, respectively. The
most common adverse event was hypokalemia (12%) and liver function
abnormalities (12 %). But hyperkalemia developed in two patients (8%).
Grade 3/4 adverse event was observed in one patient (4%).
Conclusion: Abiraterone acetate with prednisolone is potentially a favor-
able treatment in patients with metastatic castration-resistant prostate
cancer after treatment failure with docetaxel-based chemotherapy.PD4-4:
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Purpose: To compare 12 and 18 core trans-rectal ultrasound (TRUS)-bi-
opsy in patients with normal DRE (digital rectal exam) and PSA level of
4.0-20.0 ng/mL
Materials and Methods: Between 2009 to 2014, 346 patients whose DRE
were normal or rubber and serum PSA level between 4.0 and 20.0 ng/mL
underwent TRUS biopsy. Of those patients, 318 underwent 12-core biopsy
and 28 underwent 18-core biopsy. We compared the prostate cancer
detection rates and post-biopsy complications rate between the two groups.
Results: The baseline characteristics of the two groups were comparable
with regard to the mean age, prostate volume and PSA level, and PSA
density. In the 12-core prostate biopsy group, 36 (11.3%) patients were
found to have prostate cancer. On the other hand, in the 18-core prostate
biopsy group of patients, 4 (14.2%) were found to have prostate cancer.
There were no signiﬁcant different prostate cancer detection rate between
12-core biopsy and 18-core biopsy group. Besides, in patients with PSA
density (PSAD) < 0.2, the prostate cancer detection rate was slightly higher
in the 18-core biopsy group(14.3%) than in the 12-core biopsy group(9.6%),
but not statistically signiﬁcant. There was no signiﬁcant difference
complication rates as urinary retention or sepsis between the two groups.
Conclusion: We can't conclude that TRUS-guided 18-core biopsy of the
prostate is superior to the 12-core in patients with normal DRE and serum
PSA level of 4.0-20.0 ng/mL. Further studies in different population with
greater sample size are needed to draw ﬁnal conclusion.
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Radiotherapy is the main treatment modality for prostate cancer. This
study investigated the role of TGF-b1 in biological sequelae and tumor
regrowth following irradiation, which are critical for the clinical radiation
response of prostate cancer. Human and murine prostate cancer cell lines,
and corresponding hormone-refractory (HR) cells, were used to examine
the radiation response by clonogenic assays in vitro and tumor growth
delay in vivo. Biological changes after irradiation, including cell death and
tumor regrowth, were examined by experimental manipulation of TGF-b1
signaling. The correlations among tumor radiation responses, TGF-b1
levels, and regulatory T cells (Tregs) recruitment were also evaluated using
animal experiments. HR prostate cancer cells appeared more radio-
resistant and had higher expression of TGF-b1 compared to hormone-
sensitive (HS) cells. TGF-b1 expression was positively linked to irradiation
and radioresistance, as demonstrated by in vitro and in vivo experiments.
Inhibition of TGF-b1 increased tumor inhibition and DNA damage after
irradiation.When mice were irradiated with a sub-lethal dose, the
regrowth of irradiated tumors was signiﬁcantly correlated with TGF-b1
levels and Tregs accumulation in vivo. Furthermore, blocking TGF-b1
clearly attenuated Tregs accumulation and tumor regrowth following
treatment. These data demonstrate that TGF-b1 is important in deter-
mining the radiation response of prostate cancer, including tumor cell
killing and the tumor microenvironment. Therefore, concurrent treatment
with a TGF-b1 inhibitor is a potential therapeutic strategy for increasing
the radiation response of prostate cancer, particularly for more aggressive
or HR cancer cells.
